While the correction of the biotech markets downwards increases the chances of bolt-on deals, even with the reduced prices, interesting assets are not so easy to come by, so says Novartis CFO Harry Kirsch.
Anyone hoping to see Novartis AG enter into any major M&A activity will be disappointed, according to chief financial officer Harry Kirsch who reiterated that bolt-on acquisitions are the priority.
Speaking to journalists as the Swiss major unveiled a decent set of financials for the second quarter which saw sales...
The Kevin Tang-led firm will pay $4.38 per share for Cargo, which laid off most of its workforce following the failure of a Phase II CAR-T trial.
Concentra Biosciences is acquiring struggling IGM Biosciences for $1.25 per share plus a contingent value right, with the deal expected to close in August 2025.
The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.
Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.
Coartem Baby to be rolled out in eight African countries in the autumn.
Public Company Edition: A breakthrough designation, data and deals prompted big follow-on public offerings in late June and early July, including $402.5m for Cidara, $250.8m for Kymera and $230m for Dyne. Also, Revolution Medicines accessed up to $2bn from Royalty Pharma.
KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.
